Modality
Peptide
MOA
Menini
Target
FLT3
Pathway
NF-κB
CeliacCKD
Development Pipeline
Preclinical
~Dec 2022
→ ~Mar 2024
Phase 1
~Jun 2024
→ ~Sep 2025
Phase 2
Dec 2025
→ Feb 2027
Phase 2Current
NCT05262523
1,740 pts·CKD
2025-12→2026-06·Active
NCT06273778
2,841 pts·Celiac
2025-12→2027-02·Recruiting
4,581 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-052mo awayPh3 Readout· CKD
2027-02-1411mo awayPh3 Readout· Celiac
Trial Timeline
2026Q2Q3Q42027
P2/3
Active
P2/3
Recruit…
Catalysts
Ph3 Readout
2026-06-05 · 2mo away
CKD
Ph3 Readout
2027-02-14 · 11mo away
Celiac
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05262523 | Phase 2/3 | CKD | Active | 1740 | CR |
| NCT06273778 | Phase 2/3 | Celiac | Recruiting | 2841 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| Zanumavacamten | Iovance | Phase 2 | FLT3 | |
| RAR-440 | Ultragenyx | Phase 2 | FLT3 | |
| Motasacituzumab | Olema | NDA/BLA | FLT3 |